Novartis Zelnorm patient information (correction)
Executive Summary
Novartis has agreed to assess the distribution of patient prescribing information as a Phase IV commitment required for approval of its chronic constipation indication. "The Pink Sheet" had incorrectly reported that the company would assess the distribution of Zelnorm "Medguides" (1"The Pink Sheet" Aug. 30, 2004, p. 8). Zelnorm is not required to be distributed with a Medguide...